# A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs

> **NCT05459844** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Sinotau Pharmaceutical Group** · enrollment: 196 (actual)

## Conditions studied

- Neuroendocrine Tumors

## Interventions

- **DRUG:** Lutetium[177Lu] Oxodotreotide Injection
- **DRUG:** Octreotide LAR

## Key facts

- **NCT ID:** NCT05459844
- **Lead sponsor:** Sinotau Pharmaceutical Group
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-08-31
- **Primary completion:** 2024-06-26
- **Final completion:** 2028-12
- **Target enrollment:** 196 (ACTUAL)
- **Last updated:** 2025-09-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05459844

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05459844, "A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05459844. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*